Trials / Completed
CompletedNCT00507468
Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- BioCardia, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The object of this open-labeled, uncontrolled pilot study was to investigate the safety and feasibility of percutaneously transplanting autologous bone marrow (ABM) cells into the myocardium using the helical needle transendocardial (TE) delivery system in stable coronary patients with ventricular dysfunction due to chronic myocardial infarction (MI). A secondary goal was to assess the possibility that such cell injections could improve ejection fraction (EF).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Transendocaridal Transplantation of Autologous Bone Marrow | Single treatment, harvest and transplant of patients own bone marrow. Cells are delivered to the myocardium via transendocardial delivery catheter. |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2009-03-01
- Completion
- 2009-08-01
- First posted
- 2007-07-26
- Last updated
- 2009-11-03
Locations
2 sites across 1 country: Argentina
Source: ClinicalTrials.gov record NCT00507468. Inclusion in this directory is not an endorsement.